JS213

· Shanghai Junshi Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JS213, covering 2026-03-25 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors [Phase 2]

See pricing